



SUPPLEMENTAL INFORMATION DISCLOSURE CITATION NUMBER 1 (Use several sheets if necessary)				ATTY. DOCKET NO. R0032D-REG		SERIAL NO. 09/137,507	
				APPLICANT(S) Keith Roger Bley et al.			
				FILING DATE August 20, 1998		GROUP Not yet known	
U.S. PATENT DOCUMENTS							
Exam. Initial	Ref. #	Document Number	Date	Name	Class/ Subclass	Filing Date If Appropriate	
		3,931,216	Jan. 6, 1976	Franzmair	260/309.7		
FOREIGN PATENT DOCUMENTS							
	Ref. #	Document Number	Date	Country	Translation		
					Yes	No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
EXAMINER 				DATE CONSIDERED 6/21/05			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE STATEMENT

37 CFR 1.55, 1.57 and 1.58
(Use several sheets if necessary)

ATTY. DOCKET NO.
R0032D-REG

SERIAL NO.
Not yet known

APPLICANT(S)
Bley, et al.

FILING DATE
August 20, 1998

GROUP
Not yet known

U.S. PATENT DOCUMENTS

* Exr. Initial	Ref. #	Patent Number	Date	Name	Class/Subclass	Filing Date if Appropriate
<i>[Signature]</i>	AA-1	5,326,776	07/05/94	Winn et al.		
	AB-1	4,889,868	12/26/89	Huang		
	AC-1	4,588,737	05/13/86	Huang		
	AD-1	4,396,617	08/02/83	Dolman et al.		
<i>[Signature]</i>	AE-1	4,287,201	09/01/81	Olson et al.		

FOREIGN PATENT DOCUMENTS

* Exr. Initial	Ref. #	Patent Number	Date	Country	Class/Subclass	Translation Yes/No
<i>[Signature]</i>	AF-1	EP 0 017 484 B1	04/06/83	European Patent Office (EPO)		
<i>[Signature]</i>	AG-1	WO 96/30350	10/03/96	World Intellectual Property Organization (PCT)		
	AH-1	GB 2 038 305	07/23/80	United Kingdom		

OTHER DOCUMENTS


* Exr. Initial	Ref. #	Author, Title, Citation
<i>[Signature]</i>	AI-1	Murata et al., <i>Nature</i> 1997, 388, 678-682
	AJ-1	Goodman & Gillman's, <i>the Pharmacological Basis of Therapeutics</i> , 9th edition, McGraw-Hill, New York, 1996, Chapter 26, 601-616
	AK-1	Bym et al., <i>Pharmaceutical Research</i> 1995, 12(7), 945-954
<i>[Signature]</i>	AL-1	K. Anderson, <i>Pharmacological Reviews</i> 1993, 45(3), 253-308

EXAMINER'S SIGNATURE

DATE CONSIDERED

6/21/05

*EXAMINER: If a reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION NUMBER 2 (Use several sheets if necessary)				ATTY. DOCKET NO. R0032D-REG		SERIAL NO. 09/137,507	
				APPLICANT(S) Keith Roger Bley et al.			
				FILING DATE August 20, 1998		GROUP 1612	
U.S. PATENT DOCUMENTS							
Exam. Initial	Ref. #	Document Number	Date	Name	Class/ Subclass	Filing Date If Appropriat	
B	C1	4,374,143	02/15/83	Dolman	—		
FOREIGN PATENT DOCUMENTS							
	Ref. #	Document Number	Date	Country	Translation		
					Yes	No	
B	C2	EP 0 187 989 A1	07/23/86	European Patent Office (EPO)			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
EXAMINER 				DATE CONSIDERED 6/21/05			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							